Skip to main content
Clinical Trials/DRKS00022396
DRKS00022396
Completed
Not Applicable

Health economic evaluation of an integrated, cross-sectorial psycho-oncology - WP Health economic evaluation for the study Integrated, cross-sectorial psycho-oncology (isPO) - isPO

niversitätsklinikum Köln, Klinik I für Innere Medizin, Klinische Psychoonkologie, Versorgungsforschung / isPO-Konsortialführung0 sites423 target enrollmentSeptember 8, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C00-C97
Sponsor
niversitätsklinikum Köln, Klinik I für Innere Medizin, Klinische Psychoonkologie, Versorgungsforschung / isPO-Konsortialführung
Enrollment
423
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 8, 2020
End Date
September 30, 2021
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversitätsklinikum Köln, Klinik I für Innere Medizin, Klinische Psychoonkologie, Versorgungsforschung / isPO-Konsortialführung

Eligibility Criteria

Inclusion Criteria

  • patients with an initial diagnosis cancer participating in the new form of care isPO
  • insured with the participating data\-providing statutory health insurance companies BARMER, TK, AOK Rheinland/Hamburg or DAK Gesundheit
  • included isPO patients in the study until 30\.09\.2019\. The sample group is a subgroup of the IG of the isPO research project. The procedure is justified by the time delay and availability of SHI claims data. Only completely provided data sets of isPO participants within the project duration can be considered for evaluation.
  • insured persons with an initial diagnosis cancer who do not participate in isPO care and are treated in standard care
  • insured with the participating data\-providing statutory health insurance companies BARMER, TK, AOK Rheinland/Hamburg or DAK Gesundheit
  • Observation\-/ Evaluation period:
  • from the defined index date (IG: enrolled date in isPO, KG: date of coded assured initial diagnosis of cancer based on routine SHI database), costs and consequences are descriptively evaluated over a period of 12 months using SHI claims data.

Exclusion Criteria

  • no age of majority at baseline (age \< 18 years)
  • not insured with the participating data\-providing statutory health insurance companies BARMER, TK, AOK Rheinland/Hamburg or DAK Gesundheit
  • IG: enrolement in isPO care after 30\.09\.2019 (enrolement date \>\=01\.10\.2019\)
  • CG: Non\-fulfilment of the selection criteria of the comparison group from standard care (observation period, cancer diagnosis, gender, age, region) and other covariates for the application of a propensity score matching

Outcomes

Primary Outcomes

Not specified

Similar Trials